AR131644A1 - Moléculas de ácido nucleico - Google Patents
Moléculas de ácido nucleicoInfo
- Publication number
- AR131644A1 AR131644A1 ARP240100123A ARP240100123A AR131644A1 AR 131644 A1 AR131644 A1 AR 131644A1 AR P240100123 A ARP240100123 A AR P240100123A AR P240100123 A ARP240100123 A AR P240100123A AR 131644 A1 AR131644 A1 AR 131644A1
- Authority
- AR
- Argentina
- Prior art keywords
- utr
- sequence derived
- human
- chit1
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2442—Chitinase (3.2.1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/03—Acyl groups converted into alkyl on transfer (2.3.3)
- C12Y203/03001—Citrate (Si)-synthase (2.3.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11011—Protein-serine/threonine kinases (2.7.11) cAMP-dependent protein kinase (2.7.11.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01014—Chitinase (3.2.1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación se refiere a una molécula de ácido nucleico que comprende secuencias 5-UTR y/o 3-UTR que producen altos niveles de traducción. Los aspectos de la divulgación se refieren además a moléculas de ácido nucleico adecuadas para su uso como vacuna en el tratamiento y prevención de enfermedades infecciosas, incluidas las causadas por un coronavirus, composiciones que comprenden dichas moléculas de ácido nucleico y métodos para tratar o prevenir enfermedades infecciosas. Reivindicación 1: Una molécula de ácido nucleico que comprende una región 5 no traducida (5-UTR), una secuencia codificante y una región 3 no traducida (3-UTR), en donde la secuencia codificante está unida operativamente a la 5-UTR y la 3-UTR y en donde (i) la 5-UTR comprende una secuencia derivada de una 5-UTR de quitinasa-1 humana (CHIT1) y la 3-UTR comprende una secuencia derivada de una 3-UTR de citrato sintasa (CS) humana; (ii) la 5-UTR comprende una secuencia derivada de una 5-UTR de la subunidad b catalítica activada por cAMP de proteína cinasa humana (PRKACB) y la 3-UTR comprende una secuencia derivada de una 3-UTR de quitinasa-1 humana (CHIT1); (iii) la 5-UTR comprende una secuencia derivada de una 5-UTR de la subunidad b catalítica activada por cAMP de proteína cinasa humana (PRKACB) y la 3-UTR comprende una secuencia derivada de una 3-UTR de citrato sintasa (CS) humana; (iv) la 5-UTR comprende una secuencia derivada de una 5-UTR de quitinasa-1 humana (CHIT1) y la 3-UTR comprende una secuencia derivada de una 3-UTR de quitinasa-1 humana (CHIT1), en donde la secuencia codificante no deriva de quitinasa-1 humana (CHIT1); (v) la 5-UTR comprende una secuencia derivada de una 5-UTR de transaminasa 1 glutámico-oxaloacética humana (GOT1) y la 3-UTR comprende una secuencia derivada de una 3-UTR de citrato sintasa (CS) humana; o (vi) la 5-UTR comprende una secuencia derivada de una 5-UTR de transaminasa 1 glutámico-oxaloacética humana (GOT1) y la 3-UTR comprende una secuencia derivada de una 3-UTR de quitinasa-1 humana (CHIT1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363480749P | 2023-01-20 | 2023-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131644A1 true AR131644A1 (es) | 2025-04-16 |
Family
ID=89715822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100123A AR131644A1 (es) | 2023-01-20 | 2024-01-19 | Moléculas de ácido nucleico |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240277834A1 (es) |
| EP (1) | EP4651891A1 (es) |
| JP (1) | JP2026501863A (es) |
| KR (1) | KR20250145021A (es) |
| CN (1) | CN120957744A (es) |
| AR (1) | AR131644A1 (es) |
| AU (1) | AU2024209872A1 (es) |
| CL (1) | CL2025002121A1 (es) |
| CO (1) | CO2025011162A2 (es) |
| CR (1) | CR20250341A (es) |
| IL (1) | IL322194A (es) |
| MX (1) | MX2025008338A (es) |
| TW (1) | TW202446958A (es) |
| WO (1) | WO2024153793A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026104647A1 (en) | 2024-11-15 | 2026-05-21 | Astrazeneca Ab | Vaccine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP2831240B1 (en) | 2012-03-27 | 2017-11-15 | CureVac AG | Artificial nucleic acid molecules comprising a 5'top utr |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| DK4276189T3 (da) | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| US11241493B2 (en) * | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| BR112022015565A2 (pt) * | 2020-02-07 | 2022-09-27 | Modernatx Inc | Vacinas de domínio de mrna para sars-cov-2 |
-
2024
- 2024-01-19 AU AU2024209872A patent/AU2024209872A1/en active Pending
- 2024-01-19 IL IL322194A patent/IL322194A/en unknown
- 2024-01-19 CN CN202480008332.6A patent/CN120957744A/zh active Pending
- 2024-01-19 US US18/417,362 patent/US20240277834A1/en active Pending
- 2024-01-19 KR KR1020257027537A patent/KR20250145021A/ko active Pending
- 2024-01-19 TW TW113102292A patent/TW202446958A/zh unknown
- 2024-01-19 CR CR20250341A patent/CR20250341A/es unknown
- 2024-01-19 WO PCT/EP2024/051250 patent/WO2024153793A1/en not_active Ceased
- 2024-01-19 JP JP2025541736A patent/JP2026501863A/ja active Pending
- 2024-01-19 EP EP24701814.6A patent/EP4651891A1/en active Pending
- 2024-01-19 AR ARP240100123A patent/AR131644A1/es unknown
-
2025
- 2025-07-17 MX MX2025008338A patent/MX2025008338A/es unknown
- 2025-07-18 CL CL2025002121A patent/CL2025002121A1/es unknown
- 2025-08-19 CO CONC2025/0011162A patent/CO2025011162A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2025011162A2 (es) | 2025-09-08 |
| AU2024209872A1 (en) | 2025-09-04 |
| CL2025002121A1 (es) | 2025-08-22 |
| TW202446958A (zh) | 2024-12-01 |
| KR20250145021A (ko) | 2025-10-13 |
| IL322194A (en) | 2025-09-01 |
| CN120957744A (zh) | 2025-11-14 |
| JP2026501863A (ja) | 2026-01-16 |
| MX2025008338A (es) | 2025-08-01 |
| EP4651891A1 (en) | 2025-11-26 |
| US20240277834A1 (en) | 2024-08-22 |
| WO2024153793A1 (en) | 2024-07-25 |
| CR20250341A (es) | 2025-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008469A (es) | Oligonucleotidos de doble hebra modificados. | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| BR112020026125A8 (pt) | Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia | |
| BR112021026241A2 (pt) | Compostos de benzil-triazol substituído para inibição de cbl-b e outros usos dos mesmos | |
| MX2022009429A (es) | Composiciones para la inmunizacion contra virus respiratorios. | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| MX2022012985A (es) | Metodo y farmaco para tratar el sindrome de hurler. | |
| MX2022009707A (es) | Vacunas de dominio de arnm contra el sars-cov-2. | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| BR112021021921A2 (pt) | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica | |
| MX2021013420A (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica. | |
| AR088460A1 (es) | Formulaciones de etanercept estabilizadas con aminoacidos | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BRPI0818533B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| CO2023015036A2 (es) | Composición inmunogénica contra la influenza | |
| BR112022002149A2 (pt) | Composição adequada para transfectar uma molécula de ácido nucleico em uma célula, métodos para transfecção in vitro ou ex vivo de células vivas e para a produção e usos in vitro ou ex vivo da composição | |
| BR112021021726A2 (pt) | Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doença hepática | |
| AR127762A1 (es) | Composiciones inmunógenas contra el virus de la varicela-zóster y sus usos | |
| CO2025011162A2 (es) | Moléculas de ácido nucleico | |
| AR130715A1 (es) | Polinucleótidos artificiales para la expresión de proteínas | |
| MX2025006656A (es) | Oligonucleotidos antisentido para el tratamiento de enfermedades cardiovasculares | |
| BR112023001563A2 (pt) | Composições e métodos para vacinação melhorada |